US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.430 +0.030 (+2.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders ↗
Cellectis (NASDAQ:CLLS) outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through... 
Via MarketBeat
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
From Pomerantz LLP
Via GlobeNewswire
News headline image
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Participation in Upcoming Investor Conferences
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Financial Results for the Second Quarter 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Second Quarter Financial Results on August 6, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic 
From ProLynx Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Financial Results for the First Quarter 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report First Quarter Financial Results on May 11, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
From Cellectis Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool
News headline image
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces 2026 Strategy and Catalysts
From Cellectis Inc.
Via GlobeNewswire
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Arbitral Decision in Dispute with Servier
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >